
Fulltext:
81567.pdf
Embargo:
until further notice
Size:
460.6Kb
Format:
PDF
Description:
publisher's version
Publication year
2009Source
Journal of Cancer Research and Clinical Oncology, 135, 2, (2009), pp. 283-290ISSN
Publication type
Article / Letter to editor

Display more detailsDisplay less details
Organization
Gynaecology
Chemical Endocrinology
Radiation Oncology
Laboratory of Genetic, Endocrine and Metabolic Diseases
Journal title
Journal of Cancer Research and Clinical Oncology
Volume
vol. 135
Issue
iss. 2
Page start
p. 283
Page end
p. 290
Subject
IGMD 6: Hormonal regulation; ONCOL 1: Hereditary cancer and cancer-related syndromes; ONCOL 3: Translational research; ONCOL 5: Aetiology, screening and detectionAbstract
PURPOSE: To study pre-treatment serum VEGF of patients with invasive cervical cancer and its possible role as prognostic indicator. METHODS: VEGF was measured using ELISA in the largest patient group (n = 167) to date. RESULTS: Serum VEGF was significantly higher in advanced tumor stage (P = 0.01), large tumor size (tumors larger than 2 cm) (P = 0.03), and the presence of vascular space invasion (P = 0.05). Serum VEGF was associated with disease free and overall survival [DFS: Hazard Ratio (HR) = 2.61; 95% CI 1.32-5.17; P = 0.006; for OS: HR = 2.09; 95% CI 1.54-2.84; P < 0.001, respectively]. In multivariate Cox regression serum VEGF retained its prognostic value for DFS (HR = 2.10, P = 0.03) and OS (HR = 1.92, P = 0.04). CONCLUSIONS: Serum VEGF levels correlate with more advanced and more aggressive disease in cervical cancer and may be a useful prognostic factor in patients with cervical cancer.
This item appears in the following Collection(s)
- Academic publications [204859]
- Electronic publications [103204]
- Faculty of Medical Sciences [81031]
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.